Search company, investor...

Stage

Divestiture

Total Raised

$10M

Investors Count

9

Deal Terms

1

Portfolio Exits

3

Funding, Valuation & Revenue

3 Fundings

Transgenomic has raised $10M over 3 rounds.

Transgenomic's latest funding round was a PIPE for $15.08M on October 5, 2005.

Transgenomic's valuation in July 2000 was $267.07M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

10/5/2005

PIPE

$15.08M

$99M

0

FY undefined

7/24/2000

IPO

$99M

$267.07M

0

FY undefined

0

10/1/1998

Unattributed VC

$99M

$99M

0

FY undefined

0

Date

10/5/2005

7/24/2000

10/1/1998

Round

PIPE

IPO

Unattributed VC

Amount

$15.08M

$99M

$99M

Investors

Valuation

$99M

$267.07M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

Sources

0

0

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Transgenomic Deal Terms

1 Deal Term

Transgenomic's deal structure is available for 1 funding round, including their IPO from July 24, 2000.

Round

IPO

Funding Date

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

IPO

$99M

$99M

$99M

$99M

$99M

$99M

Transgenomic Investors

9 Investors

Transgenomic has 9 investors. Endeavor Capital Management invested in Transgenomic's PIPE funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

10/5/2005

10/5/2005

1
PIPE

Venture Capital

Connecticut

00/00/0000

00/00/0000

Iroquois Capital Group

Subscribe to see more

Merchant Bank

Tennessee

00/00/0000

00/00/0000

Omicron Capital

Subscribe to see more

Diversified Financial Services

New York

00/00/0000

00/00/0000

Perceptive Advisors

Subscribe to see more

Hedge Fund

New York

00/00/0000

00/00/0000

SF Capital Group

Subscribe to see more

Private Equity

New York

First funding

10/5/2005

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

10/5/2005

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Iroquois Capital Group

Omicron Capital

Perceptive Advisors

SF Capital Group

Rounds

1
PIPE

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Merchant Bank

Diversified Financial Services

Hedge Fund

Private Equity

Location

Connecticut

Tennessee

New York

New York

New York

Transgenomic Acquisitions

2 Acquisitions

Transgenomic acquired 2 companies. Their latest acquisition was Precipio on October 13, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/13/2016

Series B

$99M

$3.37M

Acquired

3

9/25/2012

Subscribe to see more

$99M

Subscribe to see more

0

Date

10/13/2016

9/25/2012

Investment Stage

Series B

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$3.37M

Note

Acquired

Subscribe to see more

Sources

3

0

Transgenomic Portfolio Exits

3 Portfolio Exits

Transgenomic has 3 portfolio exits. Their latest portfolio exit was ADS Biotec on December 01, 2015.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/1/2015

Divestiture

ADS Biotec

$99M

1

9/10/2015

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

8/6/2014

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/1/2015

9/10/2015

8/6/2014

Exit

Divestiture

Divestiture

Divestiture

Companies

ADS Biotec

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

10

10

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Transgenomic to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.

C
CAPE Technologies

CAPE Technologies specializes in high performance immunotechnology for environmental testing. The company offers a practical immunoassay kit for dioxin and furan analysis, designed to provide rapid and sensitive screening with a reasonable cost. The primary sectors served include environmental monitoring and regulatory compliance industries. It is based in South Portland, Maine.

S
SideroGen

SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.

A
Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.

K
Kelaroo

Kelaroo is a software company specializing in solutions for the pharmaceutical and biotechnology industries. The company offers a suite of proprietary software designed to simplify and streamline chemical reagent inventory management, synthesis outsourcing processes, and bioinformatics discovery programs. Kelaroo's products are tailored to enhance functionality with simple, yet powerful interfaces, without the need for extensive product training. It was founded in 2000 and is based in Solana Beach, California.

N
Neon

The company's core business is and remains the development and production of Active Pharmaceutical Ingredient and parenteral formulations in the the form of solution and Lyophilized injection, in areas like anesthialogy and oncology.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.